Results 141 to 150 of about 178,517 (322)

Proline cis/trans isomerization regulates a T cell specific tyrosine kinase [PDF]

, 2002
This dissertation examines the role of protein-protein interactions that regulate the conformation and function of the Tec family kinase, interleukin-2 tyrosine kinase (Itk).
Brazin, Kristine Nicole
core   +3 more sources

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

Successful treatment of “accelerated” chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.

Leukemia Research Reports, 2021
“Accelerated” chronic lymphocytic leukemia/small lymphocytic lymphoma (A-CLL) is a rare histological variant of CLL/SLL, which tends to exhibit an aggressive clinical behavior compared to CLL. Due to the rarity of A-CLL (
John Xie, Albert Jang, Andrew Vegel, Yasmin Hajja, Yara Mouawad, Ali Baghian, Bachir Berbari, Janet L. Schmid, Francisco Socola, Hana Safah, Nakhle S. Saba   +10 more
doaj  

Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production

Frontiers in Immunology, 2019
Complement factor H (CFH) has a pivotal role in regulating alternative complement activation through its ability to inhibit the cleavage of the central complement component C3, which links innate and humoral immunity.
Máté G. Kiss, Máté G. Kiss, Mária Ozsvár-Kozma, Mária Ozsvár-Kozma, Florentina Porsch, Florentina Porsch, Laura Göderle, Laura Göderle, Nikolina Papac-Miličević, Nikolina Papac-Miličević, Barbara Bartolini-Gritti, Barbara Bartolini-Gritti, Dimitrios Tsiantoulas, Dimitrios Tsiantoulas, Matthew C. Pickering, Christoph J. Binder, Christoph J. Binder   +16 more
doaj   +1 more source

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Blood, 2014
Chronic lymphocytic leukemia (CLL) is characterized by constitutive activation of the B-cell receptor (BCR) signaling pathway, but variable responsiveness of the BCR to antigen ligation.
J. Woyach, E. Bojnik, A. Ruppert, Matthew R. Stefanovski, V. Goettl, Kelly A. Smucker, Lisa L. Smith, J. Dubovsky, William H. Towns, J. MacMurray, Bonnie K. Harrington, Melanie E. Davis, S. Gobessi, L. Laurenti, B. Chang, J. Buggy, D. Efremov, J. Byrd, A. Johnson   +18 more
semanticscholar   +1 more source

Dendritic and T Cell Response to Influenza is Normal in the Patients with X-Linked Agammaglobulinemia [PDF]

, 2011
Introduction Influenza virus is a potential cause of severe disease in the immunocompromised. X-linked agammaglobu-linemia (XLA) is a primary immunodeficiency characterized by the lack of immunoglobulin, B cells, and plasma cells, secondary to mutation ...
A Amedei, A Plebani, AD Crockard, AM Zeman, C Kinnon, D Rastogi, D Vetrie, DJ Rawlings, E Liu, F Rosa Di, FE Lund, G Qin, H Mao, H Taneichi, J Bayry, J Zheng, J Zheng, J Zheng, JS Peiris, K Sochorova, Kwok-Tai Lam, M Paroli, M Terajima, MC Gagliardi, ME Conley, MM Epstein, NJ Horwood, NW Schmidt, P Gray, Pamela Pui-Wah Lee, PJ Linton, PP Lee, W Tu, W Tu, W Tu, Wenwei Tu, XS He, Y Kawakami, Yinping Liu, YL Lau, Yu-Lung Lau, Yuet Wu   +41 more
core   +3 more sources

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source

Bruton's Tyrosine‐Kinase‐Deficient Murine B Lymphocytes Fail to Enter S Phase when Stimulated with Anti‐Immunoglobulin Plus Interleukin‐4 [PDF]

, 1999
�. Forssell, Nilsson, Sideras
openalex   +1 more source

Inhibition of platelet-tumour cell interaction with ibrutinib reduces proliferation, migration and invasion of lung cancer cells [PDF]

, 2018
Purpose: To investigate the pharmacological role of the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, in tumour cell-platelet crosstalk in lung cancer.Methods: Human lung cancer cells A549 were treated with ibrutinib or DMSO.
Fu, Zhiqiang, Wang, Haifeng, Zhou, Qi, Zhou, Yi   +3 more
core   +2 more sources

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, EarlyView.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source